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Outcomes remain poor for patients presenting with locally advanced oral cancers and it remains 
imperative to re-evaluate adjuvant therapies in order to provide individuals with improved outcomes, 
ideally without compromising on long term quality of life.  We present current available evidence 
supporting the use of immune checkpoint inhibitors (ICI) in squamous cell carcinoma of the head and 
neck (SCCHN) and discuss trials examining the integration of ICI into the locoregional management of 
resectable SCCHN.  We focus particularly on the NICO trial which is investigating the integration of 
neoadjuvant and adjuvant ICI into the treatment of resectable locally advanced oral cavity cancers.    
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LA - Locally advanced 
OSCC - Oral Squamous Cell Cancer 
ICI - Immune Checkpoint Inhibitors 
SCCHN - Squamous Cell Cancer of the Head and Neck 
HPV - Human Papillomavirus 
NICO – Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in Oral cavity cancer 
CT scan – Computed Tomography scan  
PD1 – Programmed Cell Death Protein-1 
 

















Despite strategies to reduce local recurrence rates in individuals with locally advanced oral squamous 
cell carcinoma (LA OSCC), outcomes remain poor with 5 year survival rates remaining around 50% [1].  
There is a clear unmet need to identify therapeutic options capable of improving cure rates without 
inducing significant additional  long term morbidity.   
The immune checkpoint inhibitors (ICI) nivolumab and pembrolizumab (which target Programmed cell 
death protein 1 (PD1)) have been shown to improve survival in platinum refractory metastatic 
squamous cell carcinoma of head and neck (SCCHN) compared with second line chemotherapy 
(CheckMate 141 and Keynote 040 studies), and in the case of nivolumab, delayed time to deterioration 
in quality of life scores [2, 3].  More recently, ICI have proven to be beneficial when used in the first line 
metastatic setting (Keynote 048) [4].   
Naturally there has been enthusiasm to investigate the use of these drugs earlier in the disease 
process with the premise of priming the immune system and treating tumours when the disease 
burden is low and patients are physiologically fitter.  The hypothesis that this treatment improves 
outcomes when used in the locoregional management of SCCHN has been strengthened by studies in 
melanoma and non-small cell lung cancer where the use of adjuvant ICI has improved recurrence free 
survival for patients with high risk locally advanced disease [5].  A considerable amount of work 
investigating the integration of ICI into the multimodality treatment of SCCHN is ongoing (table 1).  
Initial results from the phase I CheckMate 358 study demonstrated that neoadjuvant nivolumab in a 
cohort of 29 patients with resectable SCCHN did not delay standard of care surgery and 48% 
experienced reduction in tumour volume on CT (Computed Tomography) imaging within one month 
of treatment [6].  The phase II NCT02641093 study published early data on 23 patients who received 
neoadjuvant pembrolizumab prior to surgical resection of high risk SCCHN with subsequent 
(chemo)radiotherapy and concurrent/adjuvant pembrolizumab.  After one neoadjuvant dose 
pathological responses were seen in 47% with increased tumour immune-cell infiltrate correlating to 
more robust responses [7].  Similarly the currently recruiting phase II NCT02296684 study reported that 











patients with human papillomavirus (HPV) negative stage III/IV SCCHN; 43% had pathological response 
after neoadjuvant treatment [8].   
Building upon these initial findings, and with an expectation that benefit might be derived in the 
curative setting, the NICO (Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in 
Oral cavity cancer) study was developed [9]. With a specific focus on patients with oral cavity cancers, 
this non-randomised phase II study explores the hypothesis that (neo)adjuvant immunotherapy works 
synergistically with (chemo)radiotherapy, priming and consolidating immune responses.  The protocol 
introduces nivolumab into the patient’s treatment prior to standard of care surgical ablation (+/- 
reconstruction), again before risk stratified (chemo)radiotherapy, and then adjuvantly (figure 1).  
Patients are eligible for inclusion if they have been diagnosed with LA OSCC (pre-operative staging T1-
4 N1-2 or T3-4 N0) and are fit enough to be considered for platinum based concurrent 
chemoradiotherapy.  In contrast to other trials, the specific focus upon the oral cavity sub-site will 
provide a cohort of patients who will benefit from intensification of therapy due to poor outcomes 
and where the low HPV prevalence will have little or no impact upon disease biology nor clinical 
outcomes [10].  This subsite also offers a rare opportunity to obtain multiple easily accessible biopsies 
throughout the treatment course in order to support vital translational research seeking to clarify 
potential biomarkers of response to ICI.   
The clinical community has embarked upon an exciting era where patients at high risk for recurrence 
can be offered clinical trial opportunities exploring escalated adjuvant regimes seeking to achieve 
improved survival outcomes without adding significantly to long-term toxicities.  Ongoing dynamic 
recruitment to studies such as NICO will enable us to come closer to this shared goal and pave the way 
for improved patient care.   
The NICO study (supported by The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool 
Clinical Trials Centre, and Bristol-Myers Squibb) is currently recruiting in multiple United Kingdom 
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Table 1:  Currently recruiting phase II/III trials investigating (neo)adjuvant checkpoint inhibitors in 
resectable SCCHN 
Clinical trial 
identifier / name 
Sponsor / 
collaborator  
Inclusion Trial Treatment Schedule 












Neoadjuvant nivolumab followed by 
surgery.  Further dose of nivolumab prior 
to adjuvant (C)RT.  Subsequent adjuvant 

















Neoadjuvant nivolumab followed by 
surgery two weeks later.  Adjuvant (C)RT 
with subsequent randomised three 
arms:  
 Adjuvant nivolumab x 6 
 Nivolumab plus ipilimumab x 6  












Neoadjuvant atezolizumab x 2 followed 
by surgery.  Adjuvant (C)RT with 




















Neoadjuvant pembrolizumab x 1 
followed by surgery.  Adjuvant (C)RT 






of Medicine / 







Cohort 1:  Neoadjuvant pembrolizumab 
x 1 followed by surgery.  Adjuvant (C)RT 
with subsequent adjuvant 
pembrolizumab x 6 in those with high 
risk pathological features. 
Cohort 2:  Neoadjuvant pembrolizumab 
x 2 followed by standard of care surgery.  
(Phase II) 














Surgical resection followed by nivolumab 
x 1 and subsequent CRT.  Maintenance 





University Leipzig / 






Surgical resection followed by adjuvant 
CRT or adjuvant CRT with concurrent 













Cohort 1:  Neoadjuvant pembrolizumab 
x 2 followed by surgery.  Adjuvant (C)RT 
with concurrent and maintenance 
pembrolizumab x 15. 
Cohort 2:  Standard of care surgery and 
adjuvant (C)RT.  (Phase III)  
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